Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Statin use and exacerbations in individuals with chronic obstructive pulmonary disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Airflow limitation in people living with HIV and matched uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Safety of pulmonary function testing: data from 20 years

    Research output: Contribution to journalLetterResearchpeer-review

  4. AHRR (cg05575921) hypomethylation marks smoking behaviour, morbidity and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Shared heritability and functional enrichment across six solid cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: We tested the hypothesis that statin use in individuals with COPD is associated with a reduced risk of exacerbations.

METHODS: We identified 5794 individuals with COPD and a measurement of C reactive protein (CRP) in the Copenhagen General Population Study (2003-2008). During 3 years of follow-up we recorded exacerbations with hospital admissions or oral corticosteroid treatment. In a nested case-control design, matching on age, gender, smoking, COPD severity and comorbidity, we estimated the association between statin use and exacerbations. In addition, we examined the association between statin use and high CRP (>3 mg/L), and the association between high CRP and exacerbations during follow-up.

RESULTS: Statin use was associated with reduced odds of exacerbations in crude analysis, OR=0.68 (95% CI 0.51 to 0.91, p=0.01), as well as in multivariable conditional logistic regression analysis, OR=0.67 (0.48 to 0.92, p=0.01). However, in the subgroup with the most severe COPD and without cardiovascular comorbidity, we observed a null association between statin use and exacerbations, OR=1.1 (0.5 to 2.1, p=0.83). Furthermore, statin use was associated with reduced odds of a high CRP, OR=0.69 (0.56 to 0.85, p<0.001), and a high CRP was associated with an increased risk of exacerbations, HR=1.62 (1.35 to 1.94, p<0.001). We estimated the percentage of excess risk of the association of statin use with exacerbations possibly mediated through a reduction of CRP to be 14% (4-51%).

CONCLUSIONS: Statin use was associated with reduced odds of exacerbations in individuals with COPD from the general population, although this was not apparent in those with the most severe COPD without cardiovascular comorbidity. Statins may thus only associate with reduced risk of exacerbations in patients with COPD with coexisting cardiovascular disease.

Original languageEnglish
JournalThorax
Volume70
Pages (from-to)33-40
ISSN0040-6376
DOIs
Publication statusPublished - 2015

Bibliographical note

Thorax 2015;70:33-40

ID: 44744350